SCHEMBL6833672

SCHEMBL6833672

c1ccc(Oc2ccc(NCc3cccnc3)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.73
MAPT P10636 3/20 0.66
ALDH1A1 P00352 2/20 0.66
KDM4E B2RXH2 1/20 0.66
LMNA P02545 1/20 0.66
HTT P42858 1/20 0.66
NAMPT P43490 1/20 0.66
MEN1 O00255 1/20 0.55
PABPC1 P11940 1/20 0.55
KMT2A Q03164 1/20 0.55
CYP3A4 P08684 3/20 0.54
CYP2C9 P11712 3/20 0.54
CYP2C19 P33261 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2D6 P10635 1/20 0.54
MAPK1 P28482 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CYP19A1 P11511 1/20 0.52
FFAR1 O14842 2/20 0.51
FFAR4 Q5NUL3 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7423017 0.88 LTA4H (0.60) LTA4HMAPTALDH1A1KDM4ELMNA
SCHEMBL30642394 0.85 LTA4H (1.00) LTA4HMAPTALDH1A1MEN1PABPC1
SCHEMBL523753 0.85 LTA4H (1.00) LTA4HMAPTALDH1A1MEN1PABPC1
SCHEMBL19198137 0.85 RAB9A (0.63) LTA4HMAPTALDH1A1KDM4ELMNA
SCHEMBL30520217 0.85 RAB9A (0.63) LTA4HMAPTALDH1A1KDM4ELMNA
SCHEMBL24517122 0.85 SCN9A (0.62) LTA4HMAPTALDH1A1KDM4ELMNA
SCHEMBL11213631 0.85 LTA4H (0.60) LTA4HMAPTALDH1A1KDM4ELMNA
SCHEMBL6727553 0.84 LTA4H (0.58) LTA4HMAPTALDH1A1KDM4ELMNA
SCHEMBL6730999 0.84 LTA4H (0.58) LTA4HMAPTALDH1A1KDM4ELMNA
SCHEMBL28374875 0.84 FFAR1 (0.67) MAPTHTTMEN1KMT2AFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US disclosed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US disclosed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP disclosed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO disclosed
US-4874775-A INHIBIT PHYTOPATHOGENS ELI LILLY AND COMPANY (US) 1989-10-17 US disclosed
EP-0206581-A2 Agriculturally-useful sulfonamides ELI LILLY AND COMPANY (US) 1986-12-30 EP disclosed
CN-86103621-A The method of the sulphonamide of preparation agriculturally useful 1986-12-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 LTA4H 1721/4885MAPT 3885/4885ALDH1A1 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.